| 3.525 -0.285 (-7.48%) | 11-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.51  |
1-year : | 8 |
| Resists | First : | 5.57 |
Second : | 6.84 |
| Pivot price | 4.66 |
|||
| Supports | First : | 3.51 |
Second : | 2.92 |
| MAs | MA(5) : | 4.04 |
MA(20) : | 4.98 |
| MA(100) : | 4.3 |
MA(250) : | 3.08 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 5.4 |
| RSI | RSI(14): 34 |
|||
| 52-week | High : | 6.94 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRME ] has closed above bottom band by 0.3%. Bollinger Bands are 27.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.11 - 4.15 | 4.15 - 4.17 |
| Low: | 3.46 - 3.49 | 3.49 - 3.51 |
| Close: | 3.48 - 3.53 | 3.53 - 3.57 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Tue, 11 Nov 2025
Prime Medicine (NYSE:PRME) Price Target Lowered to $9.00 at Chardan Capital - MarketBeat
Tue, 11 Nov 2025
Prime Medicine to Present at Jefferies Global Healthcare Conference - The Manila Times
Tue, 11 Nov 2025
Prime Medicine (Nasdaq: PRME) sets Nov. 18 fireside chat at Jefferies, live webcast, replay 90 days - Stock Titan
Mon, 10 Nov 2025
Chardan Capital Maintains Prime Medicine (PRME) Buy Recommendation - Nasdaq
Sat, 08 Nov 2025
Prime Medicine Advances Genetic Therapy Pipeline in Q3 2025 - TipRanks
Fri, 07 Nov 2025
Prime Medicine, Inc. Reports Progress on Gene Therapy Programs and Strengthens Leadership Team - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 178 (M) |
| Held by Insiders | 7.471e+007 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 19,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9738e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 787.1 % |
| Return on Equity (ttm) | -47.4 % |
| Qtrly Rev. Growth | 4.96e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -57.99 |
| EBITDA (p.s.) | -5.59775e+007 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 20.02 |
| Dividend | 0 |
| Forward Dividend | 1.577e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|